Skip to content

A clinical trial to study whether the odomos oil is safe to use in healthy childrens.

Evaluation of dermatological safety of Odomos Oil with a 48 hours closed patch skin sensitization test on healthy children - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/001309
Enrollment
24
Registered
2010-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Odomos Oil: Patch applied on upper back of children and retained for 48 hours Control Intervention1: Vaseline & Liquid paraffin: Patch applied on upper back of children and retained for

Sponsors

DABUR INDIA LIMITED
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria: ? Healthy children volunteers ? Legally acceptable representatives ready to sign the informed consent ? Subjects willing to maintain the applied patch in position for 48 hours ? Subjects of age group 2 - 12 years ? Subject has not participated in a similar investigation in the past four weeks. ? All willing parents and subjects will sign voluntarily in the parent informed consent and assent document and come for regular follow up. ? Subjects ready to follow instructions during the study period.

Exclusion criteria

Exclusion criteria: Exclusion Criteria ? Infection, allergy on the tested area ? Skin allergy antecedents or atopic subjects ? Hyper sensitivity to any component of the tested products ? Athletes and subjects with history of excessive sweating ? Cutaneous disease which may influence the study result ? Chronic illness which may influence the cutaneous state. ? Subjects on oral corticosteroid with dose >10mg/day ? Subject in an exclusion period or participating in any other cosmetic or therapeutic trial. ? Any underlying medical illness including diabetes, liver disease, HIV, or any other serious medical illness.

Design outcomes

Primary

MeasureTime frame
To evaluate the dermatological safety of Odomos Oil on skin of healthy childrens. Timepoint: evaluations will be done on Day0,2,4,7

Secondary

MeasureTime frame
To evaluate the potential allergenicity of Odomos Oil on skin of healthy childrens.Timepoint: Evaluations done on Day 0,2,4,7

Countries

India

Contacts

Public ContactMr V V Raghavan

Dabur India Limited

arun.gupta@dabur.com01204378400

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026